BSD Announces the Opening of the Center for Treatment of Children with Hyperthermia and Chemotherapy at Charité UMS
September 25 2014 - 9:15AM
Business Wire
German Joint Health Insurance Funds Reimburse Quality
Controlled Pediatric Hyperthermia Treatments of Solid
Tumors
This is the Second German Center Established for the
Treatment of Pediatric Tumors
BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”)
announced today that the Charité Universitätsmedizin Berlin
(Charité), Department of Pediatric Hematology and Oncology, in
cooperation with the Charité Department of Radiation Oncology, has
opened a center dedicated to the treatment of pediatric tumors
using hyperthermia and chemotherapy. Prof. Angelika Eggert MD,
Chair of the Department of Pediatric Hematology and Oncology as
well as President of the German Society of Pediatric Hematology and
Oncology, and Prof. Volker Budach MD, Chair of the Department of
Radiation Oncology, will oversee the center. The German Joint
Health Insurance Funds reimburse quality controlled pediatric
hyperthermia treatments of solid tumors. The quality control
parameters have been set and were published in Strahlentherapie
& Onkologie in 2012 by the IAH Interdisziplinäre Arbeitsgruppe
für Hyperthermie (Interdisciplinary Working Group for Hyperthermia)
of DEGRO (Deutsche Gesellschaft für Radioonkologie), which is the
German Society for Radiation Oncology.
The pediatric cancer treatment center was opened as a result of
the very positive published results of the UMS Dusseldorf study on
the use of hyperthermia (delivered using the BSD-2000 Hyperthermia
System), combined with chemotherapy and tumor resection, to treat
malignant germ cell tumors in children and adolescents.
(Wessalowski et al. “Regional deep hyperthermia for salvage
treatment of children and adolescents with refractory or recurrent
non-testicular malignant germ-cell tumours: an open-label,
non-randomised, single-institution, phase 2 study.” The Lancet
Oncology, 2013.) The published study demonstrated an objective
tumor reduction in 86% of the patients, with a 5-year overall
survival rate of 72% (95% CI 55-83) and a 5-year event-free
survival of 62% (95% CI 45-75), which is unmatched by any other
clinical report on recurrent childhood malignant germ-cell
tumors.
This is the second center that has opened in Germany dedicated
to the treatment of pediatric tumors using hyperthermia and
chemotherapy. The Paediatric Oncology Clinic, Haematology and
Immunology, Centre for Child and Adolescent Health, Heinrich-Heine
University, Dusseldorf was the first center.
About Charité - Universitätsmedizin Berlin
The Charité - Universitätsmedizin Berlin (Charité) is one of the
largest university hospitals in Europe and employs 3700 doctors and
scientists. Charite is an international leader in oncology research
and medical training. More than half of the German Nobel Prize
winners in medicine and physiology come from the Charité. The
Charité extends over four campuses with almost 100 clinics and
institutes bundled under 17 Charité Centers.
About the BSD-2000 Hyperthermia System
The BSD-2000 – developed and patented exclusively by BSD –
delivers localized therapeutic heating (hyperthermia) by applying
radiofrequency (RF) energy. The BSD-2000 creates a central focusing
of energy that can be electronically focused to target the shape,
size and location of the tumor, thus providing dynamic control of
the heating delivered to the tumor region. The BSD-2000 has
Humanitarian Device Exemption (HDE) marketing approval from the
U.S. Food and Drug Administration (FDA) for use in conjunction with
radiation therapy for the treatment of cervical cancer patients who
are ineligible for chemotherapy. The BSD-2000 also has CE
(Conformité Européenne) Marking approval for the commercial sale in
Europe. CE Marking approval is also recognized in many countries
outside of the EU.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and
services systems to treat cancer and benign diseases using heat
therapy delivered using focused microwave energy and radiofrequency
(RF). BSD’s product lines include ablation and hyperthermia
treatment systems. BSD’s microwave ablation system has been
developed as a stand-alone therapy to ablate and destroy soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market, and well established distribution
in the United States, Europe and Asia. BSD’s hyperthermia cancer
treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors
with heat (hyperthermia) while increasing the effectiveness of
other therapies such as radiation therapy. Certain of the Company’s
products have received regulatory approvals in the United States,
Europe and China. For further information visit BSD Medical's
website at www.BSDMedical.com.
Forward-Looking Statements
Statements contained in this press release that are not
historical facts, including statements relating to our 2014 plans,
are forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. All forward-looking
statements are subject to risks and uncertainties detailed in the
Company's filings with the Securities and Exchange Commission,
including the market demand for our MicroThermX® products and the
regulatory requirements we face. These forward-looking statements
speak only as of the date on which such statements are made, and
the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date, except as
required by law.
for BSD Medical CorporationTricia
Ross310-622-8226tross@finprofiles.com